The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
CAR-T Meeting 2022 | Making clinical trials patient-friendly
Hans Scheurer, MSc, European Medicines Agency, Amsterdam, Netherlands and Myeloma Patients Europe, Brussels, Belgium, comments on the importance of involving patient groups in the development of clinical trials. Mr Scheurer explains that healthcare professionals should communicate with patients about the design of their study and ensure that it is tailored towards their preferences and unmet needs. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.
